US21077P1084

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 24, 2025 17:05 ET  | Source: Context Therapeutics Inc. PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.…

2 months ago
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

January 14, 2025 16:58 ET  | Source: Context Therapeutics Inc. CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers…

3 months ago